The FDA will consider a supplemental new drug application for deucravacitinib for the treatment of adults with active psoriatic arthritis based on promising results from clinical trials.
Rethinking Lupus Nephritis: Are Current Approaches & Guidelines off Target?
A rheumatologist & lupus expert reviews lupus nephritis treatment, questioning proteinuria cutoffs & ACR guidelines, advocating for newer therapies & end-of-treatment biopsies.
10 Things to Know about Lupus
SLE treatment is rapidly evolving as new therapies are developed & approved. Here are 10 key insights for clinicians.
Cardiovascular Risks Similar for JAK Inhibitors & bDMARDs
Using data from registries across Europe and Canada, Aymon et al. compared the incidence of major adverse cardiac events (MACE) in patients with RA treated with JAK inhibitors, TNF inhibitors or biologic DMARDs with other modes of action over two years. The researchers did not find an increased risk of MACE with JAK inhibitors over that time frame.
How the Experts Treat Sjögren’s Disease
With no FDA-approved drugs for Sjögren’s disease, experts share strategies for managing fatigue, arthritis, dryness, and systemic issues.
Sjögren’s Dry Eye Requires Collaboration Among Eye Doctors, Rheumatologists
Sjögren’s dry eye requires collaboration between rheumatologists and ophthalmologists for optimal patient management and treatment of this quality-of-life issue.
Dazodalibep for Sjögren’s Disease
St.Clair et al. found that patients with Sjögren’s disease treated with dazodalibep experienced greater improvement in key symptoms of dryness, fatigue & pain than patients who received placebo.
Emerging Therapies for Antiphospholipid Syndrome, an Antibody-Mediated Disease
A recent A&R review explores innovative, emerging therapies for the currently incurable, antibody-mediated disease antiphospholipid syndrome.
Understanding Immunologic Complications of Measles
As measles outbreaks increase domestically & internationally, while vaccination uptake decreases in the U.S., experts discuss treatment recommendations & the immunologic consequences of measles infections in patients with rheumatic diseases.
JAK Inhibitors 101
Experts provided an in-depth review of Janus kinase (JAK) inhibitors, discussing the latest research on their use in the treatment of specific rheumatic conditions, the risks associated with them and more.
- 1
- 2
- 3
- …
- 42
- Next Page »